Shanghai Junshi Biosciences Co. Ltd
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant tumors, neurological, autoimmune, chronic metabolic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of … Read more
Shanghai Junshi Biosciences Co. Ltd (SHJBF) - Total Liabilities
Latest total liabilities as of September 2025: $5.39 Billion USD
Based on the latest financial reports, Shanghai Junshi Biosciences Co. Ltd (SHJBF) has total liabilities worth $5.39 Billion USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shanghai Junshi Biosciences Co. Ltd - Total Liabilities Trend (2014–2024)
This chart illustrates how Shanghai Junshi Biosciences Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Shanghai Junshi Biosciences Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Shanghai Junshi Biosciences Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lien Hwa Industrial Corp
TW:1229
|
Taiwan | NT$19.38 Billion |
|
Guangdong Create Century Intelligent Equipment Group Corp Ltd
SHE:300083
|
China | CN¥6.06 Billion |
|
JetBlue Airways Corp
NASDAQ:JBLU
|
USA | $14.33 Billion |
|
Shanghai Baosight Software Co Ltd B
SHG:900926
|
China | $10.23 Billion |
|
Orchid Island Capital Inc.
NYSE:ORC
|
USA | $10.30 Billion |
|
Talos Energy Inc
F:7T2
|
Germany | €3.32 Billion |
|
Kalpataru Projects International Ltd.
NSE:KPIL
|
India | ₹195.63 Billion |
|
CMB.TECH NV
NYSE:CMBT
|
USA | $5.82 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down Shanghai Junshi Biosciences Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Junshi Biosciences Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Junshi Biosciences Co. Ltd (2014–2024)
The table below shows the annual total liabilities of Shanghai Junshi Biosciences Co. Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $4.85 Billion | +20.57% |
| 2023-12-31 | $4.02 Billion | +44.58% |
| 2022-12-31 | $2.78 Billion | +2.34% |
| 2021-12-31 | $2.72 Billion | +25.30% |
| 2020-12-31 | $2.17 Billion | +51.31% |
| 2019-12-31 | $1.43 Billion | +53.17% |
| 2018-12-31 | $936.18 Million | +832.68% |
| 2017-12-31 | $100.38 Million | +347.80% |
| 2016-12-31 | $22.41 Million | +58.27% |
| 2015-12-31 | $14.16 Million | +8.34% |
| 2014-12-31 | $13.07 Million | -- |